Illumina, Inc., USA
Scott Kahn, Ph.D. joined Illumina in April 2005 as Vice President/Chief Information Officer. Prior to Illumina, Scott served as Chief Scientific Officer at Accelrys from 2001 to 2004 where he was a key figure in product development and marketing at BioCAD Inc. and Molecular Simulations Inc. Scott has over a decade of experience in computational chemistry and has guided commercial development of some of the world's most widely used simulation products. His record includes involvement in the development of analysis tools for medicinal chemistry and in the creation of commercial modeling packages. Scott received a Ph.D. in Theoretical Organic Chemistry from the University of California, followed by post-doctoral work at Cambridge University. He is a former Assistant Professor of Chemistry at the University of Illinois, Urbana-Champaign.
The decreasing costs of genome sequencing and the availability of CLIA/CAP sequencing labs have created an opportunity to characterize tumors at the molecular level. Th e molecular variability of tumors of the same histological type both suggest the importance of using genome sequencing to guide therapeutic decisions, and the challenges in understanding the significance of the somatic events of a tumor. Th is presentation will survey the state-of-the-art in current sequencing technology and its application to tumor characterization.